Continuous Blood Glucose Monitoring to Determine the Glycemic Variability in Patients Having SARS CoV-2 Infection with ARDS and Its Bearing on the Severity of the Disease

Main Article Content

Jitendra D. Lakhani
Hetal Pandya
Archit Jain
Sachin Ghadiya

Abstract

Aims and Objectives: A study to determine the effect of glycemic variability measured by continuous blood glucose monitoring as assessed by standard deviation of each SARS CoV -2 patient's mean glucose level and to correlate with the severity of the disease.

Study Design: Cross-sectional observational study of 13 patients with SARS CoV-2 infection with Acute Respiratory Distress Syndrome (ARDS) with and without diabetes.

Place and Duration of Study: Department of Medicine, Dhiraj Hospital, Smt. Bhikhiben Kanjibhai Shah Medical College and Research Institute; between June 2020 to July 2020.

Results: 13 patients of SARS CoV-2 with ARDS were enrolled in the study. The median age of the enrolled patients was 55±12 years. Out of the 13 patients, 5 patients belonged to mild and severe category of ARDS each respectively and 3 patients belonged to the moderate category of ARDS. There was a gradual rise in inflammatory markers such as serum LDH, Ferritin, CRP from mild to severe ARDS and D-dimer level was more than double in severe category as compared to the mild ARDS. Normal glycemic variability in adults is 0-3 SD, and we found that there was a significant co-relation of glycemic variability with severity of the disease evidenced by the mean standard deviation of severe ARDS patients as 27.44 SD; whereas 19.26 SD and 9.7 SD for moderate and mild ARDS patients respectively. Hypoglycemia was documented in 10 patients. The maximum stay in the hospital was that of the patients with high glycemic variability that is 22 ± 2 days

Conclusion: This preliminary study relates glycemic variability with severity of ARDS in patients of severe SARS CoV-2. Frequent episode of hypoglycemia is not uncommon and should be monitored.

Keywords:
SARSCOV-2, COVID-19, glycemic variability, continuous glucose monitoring.

Article Details

How to Cite
Lakhani, J. D., Pandya, H., Jain, A., & Ghadiya, S. (2020). Continuous Blood Glucose Monitoring to Determine the Glycemic Variability in Patients Having SARS CoV-2 Infection with ARDS and Its Bearing on the Severity of the Disease. Journal of Advances in Medicine and Medical Research, 32(16), 51-56. https://doi.org/10.9734/jammr/2020/v32i1630629
Section
Original Research Article

References

WHO Corona Virus Disease (COVID-19) Situation Report 193 and 194. Available:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ Accessed on 1st August, 2020.

WHO Corona Virus Disease (COVID-19) Dash board. Available:https://covid19.who.int Accessed on 31st July, 2020.

Gupta N, Agrawal S, Ish P, Mishra S, Gaind R, Usha G, Singh B, Sen MK, COVID 2019 working group *Safdarjung Hospital- Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India. Monaldi Archives for Chest Disease. 2020;90(1). Available:https://doi.org/10.4081/monaldi.2020.1294

Saluja M, Pillai D, Jeliya S , Bauddh N, Chandel R. COVID 19- clinical profile, radiological presentation, prognostic predictors, complications and outcome: A perspective from the Indian subcontinent. 2020;(68).

Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):507-513.

Gautier JF, Ravussin Y. A New symptom of COVID-19: loss of taste and smell. obesity (Silver Spring). 2020;28(5):848.

Mehraeen E, Behnezhad F, Salehi MA, Noori T, Harandi H, SeyedAlinaghi S. Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): A review of current evidence [In press, 2020 Jun 17]. Eur Arch Otorhinolaryngol. 2020;1-6.

Avula A, Nalleballe K, Narula N, et al. COVID-19 presenting as stroke. Brain Behav Immun. 2020;87:115-119.

Han C, Duan C, Zhang S, et al. Digestive symptoms in COVID-19 patients with mild disease severity: Clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol. 2020;115(6):916-923.

Gupta R, Hussain A, Misra A. Diabetes and COVID-19: Evidence, current status and unanswered research questions. Eur J Clin Nutr. 2020;74(6):864-870.

Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory Medicine. 2020;8(6):e46-e47.

Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID‐19. Diabetes Metab Res Rev. 2020;e3319.

DOI: 10.1002/dmrr.3319

Ceriello, Antonio, Monnier, Louis, Owens, David. Glycaemic variability in diabetes: clinical and therapeutic implications. The Lancet Diabetes & Endocrinology. 2018;7. DOI: 10.1016/S2213-8587(18)30136-0

Ferreira L, Moniz AC, Carneiro AS, Miranda AS, Fangueiro C, Fernandes D, Silva I, Palhinhas I, Lemos J, Antunes J, Leal M, Sampaio N, Faria S. The impact of glycemic variability on length of stay and mortality in diabetic patients admitted with community-acquired pneumonia or chronic obstructive pulmonary disease, Diabetes & Metabolic Syndrome: Diabetes Metab Syndr. 2019;13(1):149-153.

Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther. 2011;13(9):921-928.

Satya Krishna SV, Kota SK, Modi KD. Glycemic variability: Clinical implications. Indian J Endocrinol Metab. 2013;17(4): 611-619.

Zhou J, Li H, Ran X, Yang W, Li Q, Peng Y, Li Y, Gao X, Luan X, Wang W, Jia W. Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med Sci Monit. 2011;17:CR9–CR13.

Suh S, Kim JH. Glycemic Variability: How Do we measure it and why is it important? Diabetes Metab J. 2015;39(4): 273-282.

Krinsley JS. Glycemic variability: A strong independent predictor of mortality in critically ill patients. Crit Care Med. 2008; 36(11):3008-3013.

Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, Devries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med. 2010;38(3):838-842. DOI: 10.1097/CCM.0b013e3181cc4be9

Fanelli V, Vlachou A, Ghannadian S, Simonetti U, Slutsky AS, Zhang H. Acute respiratory distress syndrome: New definition, current and future therapeutic options. J Thorac Dis. 2013;5(3):326-334. 21.

Joshi SR, Tiwaskar MH, Shah SN. COVID 19: Diabetes and obesity API-ICP recommendations. J Assoc Physicians India. 2020;68(5):42-44.

RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report [Published online ahead of print, 2020 Jul 17]. N Engl J Med; 2020. DOI:10.1056/NEJMoa2021436

Lakhani OJ, Kumar S, Tripathi S, Desai M, Seth C. Comparison of two protocols in the management of glucocorticoid induced hyperglycemia among hospitalized patients. Indian J Endocr Metab. 2017;21: 836-44.

Hage MP, Al-Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab. 2014;5(4):77-85.

Al-Kuraishy HM, Al-Niemi MS, Hussain NR, Al-Gareeb AI, Al-Harchan NA, Al-Kurashi AH. The potential role of renin angiotensin system (RAS) and dipeptidyl peptidase-4 (DPP-4) in COVID-19: Navigating the uncharted. In selected chapters from the renin-angiotensin system. Intech Open; 2020.